| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
CNR Institute of Neurogenetics and Neuropharmacology, Cagliari, Monserrato, Italy. aporcell@unica.it
OBJECTIVE: Previous reports have shown that the Delta(9)-tetrahydrocannabinol (Delta(9)TCH), the major psychoactive cannabinoid components of marijuana, is able [corrected] to inhibit thyroid hormonal activity. The aim of this study was to characterize the CB1 functional expression in the rat thyroid by a multi-methods approach. METHODS AND RESULTS: RT-PCR was used to detect the mRNA expression of the CB1 cannabinoid receptor (17.8+/-4.0% of the normalizing reference gene beta(2) microglobulin), as well as the expression of the endocannabinoid hydrolyzing enzyme, fatty acid amide hydrolase (46.9+/-4.3% of beta(2) microglobulin), in the rat thyroid gland. The CB1-encoded protein was detected in its glycosylated form (63 kDa) by Western blot, employing a polyclonal antibody, while CB1 immunohistochemical localization showed an intracellular positive staining in both follicular and parafollicular cells. In addition, a 30% decrease in serum levels of both 3,5,3' tri-iodothyronine (T(3)) and thyroxine (T(4)) was detected 4 h after the administration of the synthetic cannabinoid receptor agonist, WIN 55,212-2 (10 mg/kg i.p.). These effects were antagonized by pretreatment with the CB1 antagonist SR 141716A (3 mg/kg i.p.); thyrotrophin levels were unaffected by both treatments. CONCLUSION: These data indicate that functional CB1 receptors which are able to modulate the release of T(3) and T(4) are expressed in the rat thyroid, and suggest a possible role of cannabinoids in the regulation of rat thyroid hormonal activity.
This article has been cited by other articles:
|
|
 |
|
  M. A. L. C. da Veiga, F. Fonseca Bloise, R. H. Costa-e-Sousa, L. L. Souza, N. A. d. S. Almeida, K. J. Oliveira, and C. C. Pazos-Moura Acute effects of endocannabinoid anandamide and CB1 receptor antagonist, AM251 in the regulation of thyrotropin secretion J. Endocrinol., November 1, 2008; 199(2): 235 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Herling, M. Gossel, G. Haschke, S. Stengelin, J. Kuhlmann, G. Muller, D. Schmoll, and W. Kramer CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E826 - E832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Prestifilippo, J. Fernandez-Solari, C. de la Cal, M. Iribarne, A. M. Suburo, V. Rettori, S. M. McCann, and J. C. Elverdin Inhibition of Salivary Secretion by Activation of Cannabinoid Receptors Experimental Biology and Medicine, September 1, 2006; 231(8): 1421 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance Endocr. Rev., February 1, 2006; 27(1): 73 - 100. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
